Senti Biosciences Inc [SNTI] stock prices are up 23.81% to $2.08 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SNTI shares have gain 20.23% over the last week, with a monthly amount glided 52.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Senti Biosciences Inc [NASDAQ: SNTI] stock has seen the most recent analyst activity on October 14, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $12. Previously, Laidlaw started tracking the stock with Buy rating on June 06, 2025, and set its price target to $5. On October 07, 2022, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $7.50 on the stock.
The stock price of Senti Biosciences Inc [SNTI] has been fluctuating between $1.26 and $16.94 over the past year. Senti Biosciences Inc [NASDAQ: SNTI] shares were valued at $2.08 at the most recent close of the market.
Analyzing the SNTI fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -11.03%, Pretax Profit Margin comes in at -9.96%, and Net Profit Margin reading is -9.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.85, Equity is -2.24 and Total Capital is -1.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Senti Biosciences Inc [NASDAQ:SNTI]’s Current Ratio is 3.26. In addition, the Quick Ratio stands at 3.26 and the Cash Ratio stands at 2.16.
Transactions by insiders
Recent insider trading involved Lu Timothy K, CEO, that happened on Feb 04 ’25 when 3922.0 shares were sold. CEO, Lu Timothy K completed a deal on Feb 06 ’25 to sell 545.0 shares. Meanwhile, Pres. & Chief Med. & Dev. Off. Rajangam Kanya sold 1297.0 shares on Feb 04 ’25.
